Recognizing and Addressing Adverse Events of Cancer Immunotherapy

Jeffrey S. Weber, MD, PhD


November 05, 2019

The introduction of immune checkpoint inhibitors has dramatically improved outcomes for patients with a variety of cancers. But these effective treatments can be associated with immune-related adverse events that occur when the medication causes the immune system to attack normal organs and tissues in the body.

Dr Jeffrey Weber, deputy director of the Perlmutter Cancer Center at NYU Langone Health, discusses common and uncommon toxicities of checkpoint inhibitors and why it is important for non-oncologists to be vigilant when patients present with such adverse events.

To help clinicians recognize and appropriately manage immunotherapy adverse events, Dr Weber draws from joint guidelines recently issued by the American Society of Clinical Oncology and the National Comprehensive Cancer Network.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.